Management and Survival of Pleural Mesothelioma: A Record Linkage Study
暂无分享,去创建一个
C. la Vecchia | E. Negri | G. Corrao | S. Gasparini | M. Bonifazi | C. Zocchetti | A. Zambelli | G. Carioli | M. Rossi | M. Franchi
[1] Giovanni Corrao,et al. Building reliable evidence from real-world data: methods, cautiousness and recommendations , 2022, Epidemiology, Biostatistics, and Public Health.
[2] C. la Vecchia,et al. International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision , 2017, Journal of global oncology.
[3] A. Santoro,et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.
[4] T. Brüning,et al. Incidence of malignant mesothelioma in Germany 2009–2013 , 2017, Cancer Causes & Control.
[5] Nick A Maskell,et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment , 2016, European Respiratory Review.
[6] J. Peto,et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] C. la Vecchia,et al. Updated mortality study of a cohort of asbestos textile workers , 2016, Cancer medicine.
[8] J. V. van Meerbeeck,et al. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. , 2015, Lung cancer.
[9] A. Husain,et al. Malignant Mesothelioma Diagnosis. , 2015, Archives of pathology & laboratory medicine.
[10] M. Berry,et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. , 2015, The Journal of surgical research.
[11] G. Corrao,et al. A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case–control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology , 2015, BMJ Open.
[12] I. Opitz. Management of malignant pleural mesothelioma-The European experience. , 2014, Journal of thoracic disease.
[13] V. Torri,et al. Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] A. Schnatter,et al. Mesothelioma in Occupational Cohort Studies: Methodological Considerations , 2014, Journal of occupational and environmental medicine.
[15] G. Corrao,et al. A new scope and a vision for record linkage studies , 2013, Epidemiology, Biostatistics, and Public Health.
[16] E. Negri,et al. Clinical use, safety and effectiveness of novel high cost anticancer therapies after marketing approval: a record linkage study , 2013, Epidemiology, Biostatistics, and Public Health.
[17] V. Rusch,et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] V. Rusch,et al. The MARS feasibility trial: conclusions not supported by data. , 2011, The Lancet. Oncology.
[19] J. Peto,et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study , 2011, The Lancet. Oncology.
[20] R. Stahel,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] C. Ragazzo. Regione Lombardia capo fila nel File F , 2009 .
[22] F. Galateau-Sallé,et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.
[23] Samy Suissa,et al. Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.
[24] C. Gridelli,et al. Multidisciplinary treatment of malignant pleural mesothelioma. , 2007, The oncologist.
[25] K. McPherson,et al. An age, period and cohort analysis of pleural cancer mortality in Europe. , 2000 .
[26] F Levi,et al. The European mesothelioma epidemic , 1999, British Journal of Cancer.
[27] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[28] A. Gown,et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.
[29] R. Alfieri,et al. New therapeutic strategies for malignant pleural mesothelioma , 2017, Biochemical pharmacology.
[30] C. la Vecchia,et al. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. , 2012, The oncologist.
[31] F. Ricceri,et al. Survival of pleural malignant mesothelioma in Italy: A population‐based study , 2009, International journal of cancer.
[32] C. la Vecchia,et al. An age, period and cohort analysis of pleural cancer mortality in Europe. , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[33] J Espinosa Arranz,et al. [Malignant mesothelioma]. , 1994, Medicina clinica.
[34] R. Deyo,et al. ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES , 1992 .
[35] Paul L. Grimaldi,et al. Diagnosis related groups: A practitioner's guide , 1982 .